Skip to main content

Advertisement

Table 2 Anthropometric and analytic variables and treatment of the atherosclerotic patients groups

From: CD36 overexpression: a possible etiopathogenic mechanism of atherosclerosis in patients with prediabetes and diabetes

Variable NG Pre DM DM p value
Anthropometric and analytical variables
 N 5 7 10 0.4
 Age (years) 59 ± 11 66 ± 14 61 ± 8 0.5
 Weight (Kg) 76.1 ± 13.7 71.8 ± 13.4 91.6 ± 24.8 0.1
 BMI (Kg/m2) 27.5 ± 3.8 26.3 ± 4.1 33 ± 3.4 0.2
 SBP (mm Hg) 131 ± 21 139 ± 18 121 ± 23 0.3
 DBP (mm Hg) 73 ± 15 81 ± 16 68 ± 9 0.2
 Glucose (mg/dL) 94 ± 5 97 ± 11 101 ± 11 0.4
 Total cholesterol (mg/dL) 153 ± 53 158 ± 38 138 ± 47 0.7
 LDL-C (mg/dL) 96 ± 40 106 ± 27 71 ± 30 0.1
 HDL-C (mg/dL) 32 ± 7 28 ± 10 41 ± 22 0.3
 Triglycerides (mg/dL) 119 (95–189) 135 (112–170) 122 (100–183) 1.0
 HbA1c (%) 5.3 ± 0.3 5.9 ± 0.2 6.5 ± 1.0 0.02
 Insulin (µU/mL) 14.2 ± 2.5 11.3 ± 6.0 13.2 ± 7.6 0.8
 HOMA index 3.3 ± 0.6 2.8 ± 1.7 3.3 ± 2.1 0.9
Cardiovascular risk factors
 Gender (% males) 80 57 80 0.5
 Arterial hypertension (%) 80 57 100 0.1
 Dyslipidemia (%) 80 57 60 0.7
 Smoking habits (%) 60 29 10 0.1
  Ex-smokers 40 14 20  
  Non-smokers 0 57 70  
 Obesity (%) 60 29 70 0.2
  Overweight 20 43 20  
  Normal weight 20 28 10  
Treatment N (%)
 Oral antidiabetics (ADO) 0 (0%) 0 (0%) 8 (80%)  
  Metformin 0 (0%) 0 (0%) 7 (70%)  
  Sulfonylureas 0 (0%) 0 (0%) 3 (30%)  
 Insulin 0 (0%) 0 (0%) 4 (40%)  
 Lipid-lowering drugs 2 (40%) 3 (42.9%) 8 (80%) 0.1
  Statins 2 (40%) 3 (42.9%) 8 (80%) 0.1
 Antihypertensives 4 (80%) 4 (57.1%) 10 (100%) 0.1
  ACE inhibitors 2 (40%) 1 (14.3%) 4 (40%) 0.4
  ARBs 0 (0%) 1 (14.3%) 5 (50%) 0.1
  Beta blockers 1 (20%) 3 (42.9%) 4 (40%) 0.4
 Antiaggregants 3 (60%) 5 (71.4%) 9 (90%) 0.2
  ASA 2 (40%) 4 (57.1%) 9 (90%) 0.1
  Clopidogrel 1 (20%) 1 (14.3%) 0 (0%) 1.0
  1. Data shown as mean ± SD